4098979
UC RESULTS: EXPLORING CLINICAL OUTCOMES AND LONG-TERM SAFETY OF A JAK INHIBITOR FOR PATIENTS WITH UC
Date
May 20, 2024
Presenter
Cleveland Clinic
Tracks
Related Products
EXHALED BREATH ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IS ASSOCIATED WITH LUMINAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS
The evaluation of volatile organic compounds (VOCs) in exhaled breath shows promise as an entirely non-invasive strategy to evaluate for inflammation with high patient acceptance…
IBD Controlled Trials II
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED CANCER RATES IN IBD PATIENTS
Oral small molecules (OSM) have demonstrated effectiveness in treating IBD. Certain studies have associated certain OSM with an increased cancer risk. We aimed to assess the cancer risk in IBD patients treated with OSM…
